Rockdale Site Acquisition - Riot acquired 200 acres of land in Rockdale for $96 million, funded by selling 1,080 bitcoin[8, 10] - The acquisition unlocks the ability to fully utilize Rockdale's 700 MW power capacity for data center leasing[10, 11] - Eliminating the ground lease saves approximately $130 million[8, 11] AMD Data Center Lease - Riot executed a data center lease with AMD for an initial capacity of 25 MW, expandable to 200 MW[8, 13] - The contract value is $311 million over the initial 10-year term[8, 13] - The initial 25 MW will be delivered in two phases, starting in January 2026 and completed in May 2026[8, 13, 15] - The lease is expected to generate $25 million in annual NOI[13] Financial Position and Funding - Riot has $406 million in total cash and 18,005 bitcoin valued at $1.7 billion as of late 2025/early 2026[19] - The company plans to fund data center initiatives primarily through the sale of bitcoin[21] - An illustrative 3,134 BTC held on the balance sheet are required to be sold for project equity financing for current developments[21] Data Center Growth and Valuation - Riot is building a 1 GW+ critical IT leasing pipeline[25, 26] - The total portfolio NOI range is estimated at $1.6-2.1 billion[27] - Riot currently trades among the lowest EV/MW multiples in the sector[31]

Financial Performance - Full Year 2025 - Net income reached $7.0 billion, resulting in diluted earnings per share of $16.59[7] - Total revenue increased by 7% year-over-year, driven by record net interest income (NII) and noninterest income[8] - Pretax, pre-provision earnings (PPNR) increased by 15% year-over-year (non-GAAP)[8] - The company achieved 5% positive operating leverage due to well-controlled expenses[8] Balance Sheet and Credit Quality - Total loans averaged $327.9 billion, a 3% increase year-over-year[9] - Total deposits averaged $439.5 billion, a 3% increase year-over-year[9] - The net loan charge-off ratio was 0.20%[8] FirstBank Acquisition - The acquisition of FirstBank closed on January 5, 2026, with a total consideration of $4.2 billion[8, 27] - FirstBank brings $16 billion in total loans and $23 billion in total deposits[28] Outlook for 2026 - Average loans are expected to increase by approximately 8%[31] - Net interest income is projected to increase by around 14%[31] - Total revenue is forecasted to increase by about 11%[31]

Acquisition Overview - Worthington Steel will acquire Kloeckner & Co for €11 per share in cash[11, 40, 57] - The implied enterprise value of the acquisition is $2.4 billion[40] - Approximately 42% of Kloeckner shares are already committed to accepting the offer[16, 39, 51] Strategic Rationale - The acquisition is expected to deliver $150 million in annual run-rate synergies by the end of FY 2028[13, 39, 47, 51, 59] - The combined company's sales are projected to be $9.5 billion, with an EBITDA margin of 70% including run-rate synergies[39, 43] - The acquisition creates the second-largest service center in North America[13, 34, 59] Financial Impact - The transaction is expected to be substantially accretive to Worthington Steel's EPS within the first full year of operation[14, 39, 44] - The expected pro forma net leverage at closing is approximately 40x[39, 51, 53, 56] - The target net leverage is approximately 25x within 24 months[13, 39, 53, 56, 59] Kloeckner's Business - Kloeckner has TTM sales of $63 billion and TTM shipments of 42 million tons[16] - Kloeckner's net debt was $12 billion as of September 30, 2025[16] - Distribution share in sales mix reduced from approximately 37% in 2021 to approximately 13% in 2025[22]

Financial Performance - Full Year 2025 (GAAP) - Revenues reached $9690 million, an increase from $9279 million in 2024[26] - Net income was $2851 million, up from $2588 million in the previous year[26] - Diluted EPS increased by +16% year-over-year (YoY)[28] - Return on Assets increased +12 bps YoY to 135%[28] - Return on Common Equity increased +73 bps YoY to 1027%[28] Financial Performance - Fourth Quarter 2025 (GAAP) - Revenues were $2475 million, compared to $2385 million in 4Q24[30] - Diluted EPS increased +21% YoY[33] - Return on Assets increased +13 bps YoY to 141%[30] - Return on Common Equity increased +112 bps YoY to 1087%[30] Balance Sheet - Average loans increased by +$11 billion QoQ[44] - Average deposits increased by +$24 billion QoQ[51] - CET1 capital ratio decreased to 1084%[85]

Investor Presentation January 2026 Forward Looking Statements This slide presentation contains "forward-looking statements" and "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995. This information and these statements, which can be identified by the fact that they do not relate strictly to historical or current facts, are made as of the date of this presentation or as of the date of the effective date of information described in this presentation, as app ...

Ouster's Core Business and Technology - Ouster is a leading global provider of digital lidar sensors and software solutions[9] - The company's physical AI architecture, embedded software, and applications offer superior cost, reliability, and performance[9] - Ouster's digital lidar technology features a fully integrated, all-semiconductor design[15, 24] - Ouster offers both scanning (OS Series) and true solid-state (DF Series) lidar sensors[20] Financial Highlights and Market Opportunity - Ouster has a strong balance sheet with $247 million in cash equivalents and short-term investments as of September 30, 2025[9] - The company is on a path to profitability[9] - Ouster targets a total addressable market (TAM) of $70 billion across automotive, industrial, robotics, and smart infrastructure[9, 37] Growth Strategy and Software Solutions - Ouster aims to achieve 30-50% annual revenue growth[68] - The company's software solutions, Ouster Gemini and BlueCity, provide precision detection, classification, and tracking[14, 36] - Ouster's software solutions generate recurring revenue at accretive margins[14] Target Markets - The robotics market presents a $14 billion TAM by 2030[38, 40] - The industrial market offers an $18 billion TAM by 2030[38, 47] - The smart infrastructure market represents a $19 billion TAM by 2030[38, 55] - The automotive market provides a $20 billion TAM by 2030[38, 61]

Sotagliflozin Program - Lexicon is on track for a 2026 resubmission of the New Drug Application (NDA) for Zynquista (sotagliflozin) for type 1 diabetes (T1D) based on STENO1 study data[12] - The SONATA-HCM Phase 3 study, evaluating approximately 500 patients with both obstructive and non-obstructive HCM, is accelerating towards 2026 enrollment completion, with topline results anticipated in Q1 2027[13] - Approximately 11 million people in the U S have either obstructive or non-obstructive HCM, but only ~1% CMI total market penetration[14, 15] Pilavapadin Program - Phase 3 development of Pilavapadin for Diabetic Peripheral Neuropathic Pain (DPNP) is planned, with potential for additional indications in Phase 2[6] - Approximately 9 million U S patients have progressive DPNP, and 60% of patients have tried multiple treatments[23] - Phase 2 studies in DPNP showed clinically meaningful efficacy of the 10mg dose, with a 2-point average daily pain score (ADPS) reduction from baseline at 12 weeks[28] LX9851 Program - IND-enabling studies for LX9851 in obesity/weight management are completed, with clinical development preparations underway[6, 38] - Lexicon achieved an initial $10 million milestone from Novo Nordisk, with the potential to achieve an additional $20 million in milestone payments in 2026, and up to $950 million in remaining potential milestones plus tiered royalties on net sales[38, 39] Financial Status - Lexicon ended 2025 with $1252 million in cash, investments, and restricted cash, sufficient to support planned operations into 2027[39]

JP Morgan Healthcare Conference January 2026 NASDAQ GS ALXO This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. This presentation also contains estimates and other statistical da ...

Financial Performance & Growth - Total revenue for 2025 reached $33.6 million, representing a 20% year-over-year growth[13] - Recurring revenue accounted for $17.8 million in 2025, making up 53% of the total revenue[14] - The company achieved a significant gross margin improvement in 2025[14] - Q4 2025 total revenue was $11.3 million, a 37% growth[14] Market Position & Strategy - Rapid Micro Biosystems' Growth Direct system is used by 75% of the top 20 global pharmaceutical companies[13, 34] - 86% of approved CAR-T manufacturers have placed Growth Direct systems[13, 35] - The company has a land and expand strategy, focusing on enterprise deployments and new geographies[31, 32] - The company has 190 cumulative system placements[13, 35] Technology & Innovation - The Growth Direct platform automates microbial quality control (MQC), reducing the process to 2 steps and halving the time to results[25] - The company has 155 cumulative system validations[13, 35] Partnerships - Strategic partnership with MilliporeSigma is expected to drive growth, margin expansion, and innovation[14]

Pipeline and Milestones - Sutro is developing a differentiated pipeline of single- and dual-payload ADCs, focusing on complex targets and overcoming resistance [12, 13] - Initial Phase 1 data for STRO-004, a Tissue Factor (TF)-targeting ADC, is expected in mid-2026 [12, 59] - An IND submission for STRO-006, an ITGB6-targeting ADC, is expected in 2026 [12, 59] - An IND submission for STRO-227, a PTK7-targeting dual-payload ADC, is expected in 2026-2027 [13, 50, 59] - The first immunostimulatory ADC (iADC) program is expected to enter the clinic in early 2026 [56, 59] STRO-004 (TF-Targeting ADC) - STRO-004 demonstrated promising anti-tumor activity in multiple TF-expressing cancer models, with a disease control rate (DCR) of 93% (28/30) and an overall response rate (ORR) of 73% (22/30) in PDX models [25] - STRO-004 is well-tolerated at 50 mg/kg in non-human primates (NHPs) [12] STRO-006 (ITGB6-Targeting ADC) - STRO-006 is designed for superior selectivity, safety, and stability, targeting ITGB6 [32] - In HNSCC PDX models, STRO-006 at 5 mg/kg showed superior anti-tumor activity compared to aITGB6 ADC (DAR4 MMAE) at 5 mg/kg, with an ORR of 71% (12/17) vs 47% (8/17) [37] - In HNSCC PDX models, STRO-006 showed ADC response (below baseline) at end of study 64% (7/11) vs aITGB6 DAR4 MMAE 27% (3/11) [38] Dual-Payload ADCs - Dual-payload ADCs have the potential to overcome resistance resulting from conventional ADCs and reduce toxicity compared to ADC combination approaches [44]